Overall, these studies confirm that dual targeting of PI3K and MEK can induce marked tumour growth inhibition in vivo, and that this anti-tumour effect can be predicted by measuring [18F]-FLT uptake at baseline and after 2 days of treatment. The gene discussed is PIK3CA; the disease is neoplasm.